Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection | Zendy

Süleyman Sayar | Zendy; Kemal Kürbüz | Zendy; Resul Kahraman | Zendy; Oğuzhan Öztürk | Zendy; Zuhal Çalışkan | Zendy; Levent Doğanay | Zendy; Kâmil Özdil | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection

Author(s) -

Süleyman Sayar,

Kemal Kürbüz,

Resul Kahraman,

Oğuzhan Öztürk,

Zuhal Çalışkan,

Levent Doğanay,

Kâmil Özdil

Publication year - 2020

Publication title -

the turkish journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.404

H-Index - 28

eISSN - 2148-5607

pISSN - 1300-4948

DOI - 10.5152/tjg.2020.19295

Subject(s) - medicine , hbsag , hepatitis b virus , hepatitis b , immunology , gastroenterology , tumor necrosis factor alpha , virology , virus

Hepatitis B reactivation (HBVR) is an important risk of treatment with tumor necrosis factor inhibitors (anti-TNF). While antiviral prophylaxis is recommended before treatment in HBsAg-positive patients, there is no clear approach for the follow-up or prophylactic treatment of patients with past hepatitis B virus (HBV) infection. The aim of this study was to evaluate patients with past HBV infection treated with anti-TNF for HBVR and/or HBVR-associated biochemical breakthrough.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research